A USA Today report found that from January through May 2020, 28 generic drugs in 405 dosages made the U.S. Food and Drug Administration’s list of drugs in shortage.
Following a setback with the company’s experimental major depressive disorder medicine in December, SAGE Therapeutics will initiate a corporate restructuring that includes halving the drug manufacturer’s employee headcount in order to focus resources on the development of the product pipeline.
Sedentary teens may be more likely than their active peers to be depressed, and a new study suggests even light exercise like walking might help reduce this risk.
Luye Pharma Group submitted a new drug application to the U.S. Food and Drug Administration for LY03005, a new chemical drug for the treatment of major depressive disorder.
Axsome Therapeutics Inc.’s oral tablet AXS-05 succeeded in reducing symptoms of major depressive disorder in a late-stage trial, taking the company a step closer to entering a multi-billion dollar market for depression treatments.
The first ever clinical study evaluating combined transcranial direct current stimulation (tDCS) and behaviour therapy could point to a new treatment for depression.
Usona Institute received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for psilocybin in the treatment of major depressive disorder (MDD).
Johnson & Johnson’s Spravato, a nasal spray for depression and potential blockbuster medicine, won recommendation for approval from a European Medicines Agency panel.
Pear Therapeutics announced the filing of a submission to the U.S. Food and Drug Administration seeking marketing authorization for Somryst, a prescription digital therapeutic (PDT) intended for use in the treatment of adults with chronic insomnia and depression.
Flow, a medical device company, launched a medication-free treatment for depression comprising a brain stimulation headset and therapy app.